PYC Therapeutics (ASX: PYC) has successfully completed dosing for the second cohort of patients in its phase 1 clinical trial for Retinitis Pigmentosa type 11 (RP11), a childhood blinding eye disease. The trial aims to evaluate the safety and tolerability of VP-001, a potential disease-modifying drug, in RP11 patients. The drug recently received Fast Track status from the US FDA. A Safety Review Committee will assess data from cohorts 1 and 2 in December to consider moving forward with dosing in the third cohort, maintaining the timeline for completion by the end of 2023.
The company may also seek approval for a fourth, higher-dose cohort in Q1 2024. PYC plans to initiate a mid/late-stage multiple-dose clinical trial in Q2 2024, with initial data across safety, tolerability, and efficacy expected in 2024. RP11 is a rare disease caused by PRPF31 gene deficiency, and VP-001 aims to restore gene expression using PYC's drug delivery technology. PYC Therapeutics is a biotechnology company focused on RNA therapies for genetic diseases, pioneering drug candidates for blinding eye diseases and other conditions.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 20, 2024
Nov 20, 2024
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
